Comparison of The International Federation of Gynecology and Obstetrics (FIGO) 2018 and 2009 Staging Systems for Operated Cervical Carcinoma

Basit Öğe Kaydı
dc.authorscopusid55154035200
dc.authorscopusid57221848706
dc.authorscopusid55788286200
dc.authorscopusid6602600548
dc.contributor.authorSert, Fatma
dc.contributor.authorBalci, Beril
dc.contributor.authorAlanyali, Senem
dc.contributor.authorOzsaran, Zeynep
dc.date.accessioned2023-01-12T20:18:54Z
dc.date.available2023-01-12T20:18:54Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractOBJECTIVE The purpose of the study was to compare FIGO 2009 and 2018 uterine cervical carcinoma staging systems in terms of patient distribution and efficacy in predicting treatment outcome in patients treated with surgery and adjuvant radiotherapy (RT)+/-concomitant chemotherapy (CT). METHODS The records of 184 uterine cervical cancer patients treated with post-operative RT/RCT from 2007 to 2017 were retrospectively reviewed. Surgical procedure was in the form of Wertheim surgery in 96 patients (52%) and pelvic lymph node dissection was performed in 32 patients (17.5%). One hundred and sixty-six patients (87.5%) received both external RT and intracavitary brachytherapy, and 23 (12.5%) patients were treated only with external RT. RESULTS The median follow-up time was 61.5 months (range, 8-132 moths). One hundred and fifty-one (82%) patients were alive, and 144 (94%) of these were free of disease at the time of this analysis. The median time for locoregional failure and distant metastasis were 25 months (range, 8-88 months) and 38 months (range, 12-118 months). Stage migration was recorded in 130 patients (70.7%) in our series when the International Federation of Gynecology and Obstetrics (FIGO) 2018 staging system was used. The most remarkable stage migration was detected for Stage I patients. A total of 119 (64.6%) patients with Stage I showed stage migration. Five-year locoregional control, disease-free survival, disease-specific survival, and overall survival rates were 91%, 88%, 91%, and 83%, respectively. CONCLUSION The updated FIGO staging system for invasive cervical cancer incorporates imaging and pathological findings. Our results suggest us that the major improvement of 2018 staging system for uterine cervical carcinoma is that it produced better discrimination in terms of survival outcome in patients with lymph node metastases both pelvic and para-aortic.en_US
dc.identifier.doi10.5505/tjo.2021.2786
dc.identifier.endpage314en_US
dc.identifier.issn1300-7467
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85116300217en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage306en_US
dc.identifier.trdizinid505353en_US
dc.identifier.urihttps://doi.org/10.5505/tjo.2021.2786
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/505353
dc.identifier.urihttps://hdl.handle.net/11454/78969
dc.identifier.volume36en_US
dc.identifier.wosWOS:000744206800008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofTurk Onkoloji Dergisi-Turkish Journal Of Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCancer stagingen_US
dc.subjectFIGO stagingen_US
dc.subjectradiotherapyen_US
dc.subjectuterin cervical carcinomaen_US
dc.subjectCanceren_US
dc.titleComparison of The International Federation of Gynecology and Obstetrics (FIGO) 2018 and 2009 Staging Systems for Operated Cervical Carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu